Faculty Appointments
Associate Professor of Medicine
Education
M.P.H., Public Health, Vanderbilt University, Nashville, TennesseeM.D., MEDICINE, University of Alabama, Birmingham, AlabamaB.S., Biomedical Sciences, University of South Alabama, Mobile, Alabama
Office Address
A2200 MCN
Vanderbilt University
Nashville, TN 37232-2582
Vanderbilt University
Nashville, TN 37232-2582
Research Keywords
Clinical outcomes/translational HIV research; antiretroviral toxicity; mitochondrial genomics and oxidant stress
Clinical Research Keywords
HIV/AIDS; antiretroviral therapy; mitochondrial genomics; oxidant stress; drug abuse
Publications
Koethe JR, Dee K, Bian A, Shintani A, Turner M, Bebawy S, Sterling TR, Hulgan T. Circulating interleukin-6, soluble CD14, and other inflammation biomarker levels differ between obese and nonobese HIV-infected adults on antiretroviral therapy. AIDS Res. Hum. Retroviruses [print-electronic]. 2013 Jul; 29(7): 1019-25. PMID: 23469772, PMCID: PMC3685684, DOI: 10.1089/AID.2013.0016, ISSN: 1931-8405.
Koethe JR, Bian A, Shintani AK, Wester CW, Erdem H, Hulgan T. An association between adiposity and serum levels of macrophage inflammatory protein-1a and soluble CD14 in HIV-infected adults: results from a cross-sectional study. Antivir. Ther. (Lond.) [print-electronic]. 2013; 18(5): 729-33. PMID: 23748193, PMCID: PMC3923367, DOI: 10.3851/IMP2645, ISSN: 2040-2058.
Rasbach DA, Desruisseau AJ, Kipp AM, Stinnette S, Kheshti A, Shepherd BE, Sterling TR, Hulgan T, McGowan CC, Qian HZ. Active cocaine use is associated with lack of HIV-1 virologic suppression independent of nonadherence to antiretroviral therapy: use of a rapid screening tool during routine clinic visits. AIDS Care [print-electronic]. 2013; 25(1): 109-17. PMID: 22670566, PMCID: PMC3443534, DOI: 10.1080/09540121.2012.687814, ISSN: 1360-0451.
Holzinger ER, Hulgan T, Ellis RJ, Samuels DC, Ritchie MD, Haas DW, Kallianpur AR, Bloss CS, Clifford DB, Collier AC, Gelman BB, Marra CM, McArthur JC, McCutchan JA, Morgello S, Simpson DM, Franklin DR, Rosario D, Selph D, Letendre S, Grant I, . Mitochondrial DNA variation and HIV-associated sensory neuropathy in CHARTER. J. Neurovirol [print-electronic]. 2012 Dec; 18(6): 511-20. PMID: 23073667, PMCID: PMC3587171, DOI: 10.1007/s13365-012-0133-y, ISSN: 1538-2443.
Koethe JR, Bian A, Shintani AK, Boger MS, Mitchell VJ, Erdem H, Hulgan T. Serum leptin level mediates the association of body composition and serum C-reactive protein in HIV-infected persons on antiretroviral therapy. AIDS Res. Hum. Retroviruses [print-electronic]. 2012 Jun; 28(6): 552-7. PMID: 22145933, PMCID: PMC3358098, DOI: 10.1089/AID.2011.0232, ISSN: 1931-8405.
Hulgan T, Robbins GK, Kalams SA, Samuels DC, Grady B, Shafer R, Murdock DG, Selph D, Haas DW, Pollard RB, . T cell activation markers and African mitochondrial DNA haplogroups among non-Hispanic black participants in AIDS clinical trials group study 384. PLoS ONE [print-electronic]. 2012; 7(8): e43803. PMID: 22970105, PMCID: PMC3433792, PII: PONE-D-12-11386, DOI: 10.1371/journal.pone.0043803, ISSN: 1932-6203.
Grady BJ, Samuels DC, Robbins GK, Selph D, Canter JA, Pollard RB, Haas DW, Shafer R, Kalams SA, Murdock DG, Ritchie MD, Hulgan T, . Mitochondrial genomics and CD4 T-cell count recovery after antiretroviral therapy initiation in AIDS clinical trials group study 384. J. Acquir. Immune Defic. Syndr. 2011 Dec 12/1/2011; 58(4): 363-70. PMID: 21792066, PMCID: PMC3204178, DOI: 10.1097/QAI.0b013e31822c688b, ISSN: 1944-7884.
Haas DW, Kuritzkes DR, Ritchie MD, Amur S, Gage BF, Maartens G, Masys D, Fellay J, Phillips E, Ribaudo HJ, Freedberg KA, Petropoulos C, Manolio TA, Gulick RM, Haubrich R, Kim P, Dehlinger M, Abebe R, Telenti A, . Pharmacogenomics of HIV therapy: summary of a workshop sponsored by the National Institute of Allergy and Infectious Diseases. HIV Clin Trials. 2011 Sep; 12(5): 277-85. PMID: 22180526, PMCID: PMC3322423, PII: H4HV83200516XH08, DOI: 10.1310/hct1205-277, ISSN: 1528-4336.
Qian HZ, Stinnette SE, Rebeiro PF, Kipp AM, Shepherd BE, Samenow CP, Jenkins CA, No P, McGowan CC, Hulgan T, Sterling TR. The relationship between injection and noninjection drug use and HIV disease progression. J Subst Abuse Treat [print-electronic]. 2011 Jul; 41(1): 14-20. PMID: 21349679, PMCID: PMC3110534, PII: S0740-5472(11)00014-6, DOI: 10.1016/j.jsat.2011.01.007, ISSN: 1873-6483.
Hulgan T, Haubrich R, Riddler SA, Tebas P, Ritchie MD, McComsey GA, Haas DW, Canter JA. European mitochondrial DNA haplogroups and metabolic changes during antiretroviral therapy in AIDS Clinical Trials Group Study A5142. AIDS. 2011 Jan 1/2/2011; 25(1): 37-47. PMID: 20871389, PMCID: PMC2995830, DOI: 10.1097/QAD.0b013e32833f9d02, ISSN: 1473-5571.
McGowan CC, Weinstein DD, Samenow CP, Stinnette SE, Barkanic G, Rebeiro PF, Sterling TR, Moore RD, Hulgan T. Drug use and receipt of highly active antiretroviral therapy among HIV-infected persons in two U.S. clinic cohorts. PLoS ONE. 2011; 6(4): e18462. PMID: 21541016, PMCID: PMC3081810, DOI: 10.1371/journal.pone.0018462, ISSN: 1932-6203.
Alves TP, Hulgan T, Wu P, Sterling TR, Stinnette SE, Rebeiro PF, Vincz AJ, Bruce M, Ikizler TA. Race, kidney disease progression, and mortality risk in HIV-infected persons. Clin J Am Soc Nephrol [print-electronic]. 2010 Dec; 5(12): 2269-75. PMID: 20876679, PMCID: PMC2994089, PII: CJN.00520110, DOI: 10.2215/CJN.00520110, ISSN: 1555-905X.
Shepherd BE, Jenkins CA, Rebeiro PF, Stinnette SE, Bebawy SS, McGowan CC, Hulgan T, Sterling TR. Estimating the optimal CD4 count for HIV-infected persons to start antiretroviral therapy. Epidemiology. 2010 Sep; 21(5): 698-705. PMID: 20585252, PMCID: PMC3086582, DOI: 10.1097/EDE.0b013e3181e97737, ISSN: 1531-5487.
Canter JA, Robbins GK, Selph D, Clifford DB, Kallianpur AR, Shafer R, Levy S, Murdock DG, Ritchie MD, Haas DW, Hulgan T, , . African mitochondrial DNA subhaplogroups and peripheral neuropathy during antiretroviral therapy. J. Infect. Dis. 2010 Jun 6/1/2010; 201(11): 1703-7. PMID: 20402593, PMCID: PMC2862090, DOI: 10.1086/652419, ISSN: 1537-6613.
Melekhin VV, Shepherd BE, Jenkins CA, Stinnette SE, Rebeiro PF, Bebawy SS, Rasbach DA, Hulgan T, Sterling TR. Postpartum discontinuation of antiretroviral therapy and risk of maternal AIDS-defining events, non-AIDS-defining events, and mortality among a cohort of HIV-1-infected women in the United States. AIDS Patient Care STDS. 2010 May; 24(5): 279-86. PMID: 20438375, PMCID: PMC2875979, DOI: 10.1089/apc.2009.0283, ISSN: 1557-7449.
Boger MS, Shintani A, Redhage LA, Mitchell V, Haas DW, Morrow JD, Hulgan T. Highly sensitive C-reactive protein, body mass index, and serum lipids in HIV-infected persons receiving antiretroviral therapy: a longitudinal study. J. Acquir. Immune Defic. Syndr. 2009 Dec 12/1/2009; 52(4): 480-7. PMID: 19911471, PMCID: PMC2794651, ISSN: 1944-7884.
Hulgan T, Donahue JP, Smeaton L, Pu M, Wang H, Lederman MM, Smith K, Valdez H, Pilcher C, Haas DW, . Oral cyclosporin A inhibits CD4 T cell P-glycoprotein activity in HIV-infected adults initiating treatment with nucleoside reverse transcriptase inhibitors. Eur. J. Clin. Pharmacol. 2009 Nov; 65(11): 1081-8. PMID: 19779705, PMCID: PMC2873632, DOI: 10.1007/s00228-009-0725-5, ISSN: 1432-1041.
Shepherd BE, Sterling TR, Moore RD, Raffanti SP, Hulgan T. Cross-cohort heterogeneity encountered while validating a model for HIV disease progression among antiretroviral initiators. J Clin Epidemiol [print-electronic]. 2009 Jul; 62(7): 729-37. PMID: 19108987, PMCID: PMC2747519, PII: S0895-4356(08)00257-6, DOI: 10.1016/j.jclinepi.2008.09.002, ISSN: 1878-5921.
Redhage LA, Shintani A, Haas DW, Emeagwali N, Markovic M, Oboho I, Mwenya C, Erdem H, Acosta EP, Morrow JD, Hulgan T. Clinical factors associated with plasma F2-isoprostane levels in HIV-infected adults. HIV Clin Trials. 2009 May; 10(3): 181-92. PMID: 19632957, PMCID: PMC2891063, PII: BG421Q1XL1393227, DOI: 10.1310/hct1003-181, ISSN: 1528-4336.
Kallianpur AR, Hulgan T. Pharmacogenetics of nucleoside reverse-transcriptase inhibitor-associated peripheral neuropathy. Pharmacogenomics. 2009 Apr; 10(4): 623-37. PMID: 19374518, PMCID: PMC2706211, DOI: 10.2217/pgs.09.14, ISSN: 1744-8042.
Lemly DC, Shepherd BE, Hulgan T, Rebeiro P, Stinnette S, Blackwell RB, Bebawy S, Kheshti A, Sterling TR, Raffanti SP. Race and sex differences in antiretroviral therapy use and mortality among HIV-infected persons in care. J. Infect. Dis. 2009 Apr 4/1/2009; 199(7): 991-8. PMID: 19220139, PII: 10.1086/597124, DOI: 10.1086/597124, ISSN: 0022-1899.
Asad S, Hulgan T, Raffanti SP, Daugherty J, Ray W, Sterling TR. Sociodemographic factors predict early discontinuation of HIV non-nucleoside reverse transcriptase inhibitors and protease inhibitors. J Natl Med Assoc. 2008 Dec; 100(12): 1417-24. PMID: 19110909, PMCID: PMC3816354, ISSN: 1943-4693.
Hulgan T. High-concentration capsaicin reduced pain in patients with HIV-associated polyneuropathy. Evid Based Med. 2008 Dec; 13(6): 183. PMID: 19043041, PII: 13/6/183, DOI: 10.1136/ebm.13.6.183, ISSN: 1473-6810.
El-Bejjani D, Hazen SL, Mackay W, Glass NE, Hulgan T, Tungsiripat M, McComsey GA. Higher plasma myeloperoxidase levels are not associated with an increased risk for cardiovascular events in HIV-infected adults. HIV Clin Trials. 2008 May; 9(3): 207-11. PMID: 18547908, PMCID: PMC2829429, PII: 0225W61M842505T2, DOI: 10.1310/hct0903-207, ISSN: 1528-4336.
Hulgan T, Klausner JD. Phosphodiesterase type-5 inhibitors and the reemerging HIV epidemic [letter]. JAMA. 2008 Mar 3/26/2008; 299(12): 1426. PMID: 18364484, PII: 299/12/1426-a, DOI: 10.1001/jama.299.12.1426, ISSN: 1538-3598.
Hulgan T, Tebas P, Canter JA, Mulligan K, Haas DW, Dubé M, Grinspoon S, Robbins GK, Motsinger AA, Kallianpur AR, . Hemochromatosis gene polymorphisms, mitochondrial haplogroups, and peripheral lipoatrophy during antiretroviral therapy. J. Infect. Dis. 2008 Mar 3/15/2008; 197(6): 858-66. PMID: 18419350, DOI: 10.1086/528697, ISSN: 0022-1899.
Canter JA, Haas DW, Kallianpur AR, Ritchie MD, Robbins GK, Shafer RW, Clifford DB, Murdock DG, Hulgan T. The mitochondrial pharmacogenomics of haplogroup T: MTND2*LHON4917G and antiretroviral therapy-associated peripheral neuropathy. Pharmacogenomics J [print-electronic]. 2008 Feb; 8(1): 71-7. PMID: 17684475, PII: 6500470, DOI: 10.1038/sj.tpj.6500470, ISSN: 1470-269X.
Motsinger AA, Haas DW, Hulgan T, Ritchie MD. Human genomic association studies: a primer for the infectious diseases specialist. J. Infect. Dis [print-electronic]. 2007 Jun 6/15/2007; 195(12): 1737-44. PMID: 17492588, PII: JID37481, DOI: 10.1086/518247, ISSN: 0022-1899.
Bress JN, Hulgan T, Lyon JA, Johnston CP, Lehmann H, Sterling TR. Agreement of decision analyses and subsequent clinical studies in infectious diseases. Am. J. Med. 2007 May; 120(5): 461.e1-9. PMID: 17466659, PMCID: PMC1909755, PII: S0002-9343(06)01149-1, DOI: 10.1016/j.amjmed.2006.08.032, ISSN: 1555-7162.
Oswald-Richter K, Grill SM, Leelawong M, Tseng M, Kalams SA, Hulgan T, Haas DW, Unutmaz D. Identification of a CCR5-expressing T cell subset that is resistant to R5-tropic HIV infection. PLoS Pathog. 2007 Apr; 3(4): e58. PMID: 17465678, PMCID: PMC1857714, PII: 06-PLPA-RA-0420R2, DOI: 10.1371/journal.ppat.0030058, ISSN: 1553-7374.
Hulgan T, Shepherd BE, Raffanti SP, Fusco JS, Beckerman R, Barkanic G, Sterling TR. Absolute count and percentage of CD4+ lymphocytes are independent predictors of disease progression in HIV-infected persons initiating highly active antiretroviral therapy. J. Infect. Dis [print-electronic]. 2007 Feb 2/1/2007; 195(3): 425-31. PMID: 17205482, PII: JID36919, DOI: 10.1086/510536, ISSN: 0022-1899.
Hulgan T, Haas DW. Toward a pharmacogenetic understanding of nucleotide and nucleoside analogue toxicity [editorial]. J. Infect. Dis [print-electronic]. 2006 Dec 12/1/2006; 194(11): 1471-4. PMID: 17083029, PII: JID36983, DOI: 10.1086/508550, ISSN: 0022-1899.
Hulgan T, Hughes M, Sun X, Smeaton LM, Terry E, Robbins GK, Shafer RW, Clifford DB, McComsey GA, Canter JA, Morrow JD, Haas DW. Oxidant stress and peripheral neuropathy during antiretroviral therapy: an AIDS clinical trials group study. J. Acquir. Immune Defic. Syndr. 2006 Aug 8/1/2006; 42(4): 450-4. PMID: 16791116, DOI: 10.1097/01.qai.0000226792.16216.1c, ISSN: 1525-4135.
Kallianpur AR, Hulgan T, Canter JA, Ritchie MD, Haines JL, Robbins GK, Shafer RW, Clifford DB, Haas DW. Hemochromatosis (HFE) gene mutations and peripheral neuropathy during antiretroviral therapy. AIDS. 2006 Jul 7/13/2006; 20(11): 1503-13. PMID: 16847405, PII: 00002030-200607130-00005, DOI: 10.1097/01.aids.0000237366.56864.3c, ISSN: 0269-9370.
Hulgan T, Raffanti S, Kheshti A, Blackwell RB, Rebeiro PF, Barkanic G, Ritz B, Sterling TR. CD4 lymphocyte percentage predicts disease progression in HIV-infected patients initiating highly active antiretroviral therapy with CD4 lymphocyte counts >350 lymphocytes/mm3. J. Infect. Dis [print-electronic]. 2005 Sep 9/15/2005; 192(6): 950-7. PMID: 16107946, PII: JID33585, DOI: 10.1086/432955, ISSN: 0022-1899.
Hulgan T, Haas DW, Haines JL, Ritchie MD, Robbins GK, Shafer RW, Clifford DB, Kallianpur AR, Summar M, Canter JA. Mitochondrial haplogroups and peripheral neuropathy during antiretroviral therapy: an adult AIDS clinical trials group study. AIDS. 2005 Sep 9/2/2005; 19(13): 1341-9. PMID: 16103764, PII: 00002030-200509020-00001, ISSN: 0269-9370.
Hulgan T, Sterling TR, Daugherty J, Arbogast PG, Raffanti S, Ray W. Prescribing of contraindicated protease inhibitor and statin combinations among HIV-infected persons. J. Acquir. Immune Defic. Syndr. 2005 Mar 3/1/2005; 38(3): 277-82. PMID: 15735444, PII: 00126334-200503010-00005, ISSN: 1525-4135.
Haas DW, Ribaudo HJ, Kim RB, Tierney C, Wilkinson GR, Gulick RM, Clifford DB, Hulgan T, Marzolini C, Acosta EP. Pharmacogenetics of efavirenz and central nervous system side effects: an Adult AIDS Clinical Trials Group study. AIDS. 2004 Dec 12/3/2004; 18(18): 2391-400. PMID: 15622315, PII: 00002030-200412030-00006, ISSN: 0269-9370.
Hulgan T, Rosenbloom ST, Hargrove F, Talbert DA, Arbogast PG, Bansal P, Miller RA, Kernodle DS. Oral quinolones in hospitalized patients: an evaluation of a computerized decision support intervention. J. Intern. Med. 2004 Oct; 256(4): 349-57. PMID: 15367178, PII: JIM1375, DOI: 10.1111/j.1365-2796.2004.01375.x, ISSN: 0954-6820.
Chan SY, Hulgan T, D'Aquila RT. The Role of Baseline HIV-1 Resistance Testing in Patients with Established Infection. Curr Infect Dis Rep. 2004 Jun; 6(3): 243-9. PMID: 15142489, ISSN: 1523-3847.
Hulgan T, Morrow J, D'Aquila RT, Raffanti S, Morgan M, Rebeiro P, Haas DW. Oxidant stress is increased during treatment of human immunodeficiency virus infection. Clin. Infect. Dis [print-electronic]. 2003 Dec 12/15/2003; 37(12): 1711-7. PMID: 14689356, PII: CID31711, DOI: 10.1086/379776, ISSN: 1537-6591.
Haas DW, Johnson BW, Spearman P, Raffanti S, Nicotera J, Schmidt D, Hulgan T, Shepard R, Fiscus SA. Two phases of HIV RNA decay in CSF during initial days of multidrug therapy. Neurology. 2003 Nov 11/25/2003; 61(10): 1391-6. PMID: 14638961, ISSN: 1526-632X.
Hulgan T, Donahue JP, Hawkins C, Unutmaz D, D'Aquila RT, Raffanti S, Nicotera F, Rebeiro P, Erdem H, Rueff M, Haas DW. Implications of T-cell P-glycoprotein activity during HIV-1 infection and its therapy. J. Acquir. Immune Defic. Syndr. 2003 Oct 10/1/2003; 34(2): 119-26. PMID: 14526200, ISSN: 1525-4135.
Donahue JP, Dowdy D, Ratnam KK, Hulgan T, Price J, Unutmaz D, Nicotera J, Raffanti S, Becker M, Haas DW. Effects of nelfinavir and its M8 metabolite on lymphocyte P-glycoprotein activity during antiretroviral therapy. Clin. Pharmacol. Ther. 2003 Jan; 73(1): 78-86. PMID: 12545146, PII: S0009923602176120, DOI: 10.1067/mcp.2003.11, ISSN: 0009-9236.
Sherertz RJ, Ely EW, Westbrook DM, Gledhill KS, Streed SA, Kiger B, Flynn L, Hayes S, Strong S, Cruz J, Bowton DL, Hulgan T, Haponik EF. Education of physicians-in-training can decrease the risk for vascular catheter infection. Ann. Intern. Med. 2000 Apr 4/18/2000; 132(8): 641-8. PMID: 10766683, PII: 200004180-00007, ISSN: 0003-4819.
Moore RB, Hulgan TM, Green JW, Jenkins LD. Increased susceptibility of the sickle cell membrane Ca2+ + Mg(2+)-ATPase to t-butylhydroperoxide: protective effects of ascorbate and desferal. Blood. 1992 Mar 3/1/1992; 79(5): 1334-41. PMID: 1531618, ISSN: 0006-4971.
Koethe JR, Bian A, Shintani AK, Wester CW, Erdem H, Hulgan T. An association between adiposity and serum levels of macrophage inflammatory protein-1a and soluble CD14 in HIV-infected adults: results from a cross-sectional study. Antivir. Ther. (Lond.) [print-electronic]. 2013; 18(5): 729-33. PMID: 23748193, PMCID: PMC3923367, DOI: 10.3851/IMP2645, ISSN: 2040-2058.
Rasbach DA, Desruisseau AJ, Kipp AM, Stinnette S, Kheshti A, Shepherd BE, Sterling TR, Hulgan T, McGowan CC, Qian HZ. Active cocaine use is associated with lack of HIV-1 virologic suppression independent of nonadherence to antiretroviral therapy: use of a rapid screening tool during routine clinic visits. AIDS Care [print-electronic]. 2013; 25(1): 109-17. PMID: 22670566, PMCID: PMC3443534, DOI: 10.1080/09540121.2012.687814, ISSN: 1360-0451.
Holzinger ER, Hulgan T, Ellis RJ, Samuels DC, Ritchie MD, Haas DW, Kallianpur AR, Bloss CS, Clifford DB, Collier AC, Gelman BB, Marra CM, McArthur JC, McCutchan JA, Morgello S, Simpson DM, Franklin DR, Rosario D, Selph D, Letendre S, Grant I, . Mitochondrial DNA variation and HIV-associated sensory neuropathy in CHARTER. J. Neurovirol [print-electronic]. 2012 Dec; 18(6): 511-20. PMID: 23073667, PMCID: PMC3587171, DOI: 10.1007/s13365-012-0133-y, ISSN: 1538-2443.
Koethe JR, Bian A, Shintani AK, Boger MS, Mitchell VJ, Erdem H, Hulgan T. Serum leptin level mediates the association of body composition and serum C-reactive protein in HIV-infected persons on antiretroviral therapy. AIDS Res. Hum. Retroviruses [print-electronic]. 2012 Jun; 28(6): 552-7. PMID: 22145933, PMCID: PMC3358098, DOI: 10.1089/AID.2011.0232, ISSN: 1931-8405.
Hulgan T, Robbins GK, Kalams SA, Samuels DC, Grady B, Shafer R, Murdock DG, Selph D, Haas DW, Pollard RB, . T cell activation markers and African mitochondrial DNA haplogroups among non-Hispanic black participants in AIDS clinical trials group study 384. PLoS ONE [print-electronic]. 2012; 7(8): e43803. PMID: 22970105, PMCID: PMC3433792, PII: PONE-D-12-11386, DOI: 10.1371/journal.pone.0043803, ISSN: 1932-6203.
Grady BJ, Samuels DC, Robbins GK, Selph D, Canter JA, Pollard RB, Haas DW, Shafer R, Kalams SA, Murdock DG, Ritchie MD, Hulgan T, . Mitochondrial genomics and CD4 T-cell count recovery after antiretroviral therapy initiation in AIDS clinical trials group study 384. J. Acquir. Immune Defic. Syndr. 2011 Dec 12/1/2011; 58(4): 363-70. PMID: 21792066, PMCID: PMC3204178, DOI: 10.1097/QAI.0b013e31822c688b, ISSN: 1944-7884.
Haas DW, Kuritzkes DR, Ritchie MD, Amur S, Gage BF, Maartens G, Masys D, Fellay J, Phillips E, Ribaudo HJ, Freedberg KA, Petropoulos C, Manolio TA, Gulick RM, Haubrich R, Kim P, Dehlinger M, Abebe R, Telenti A, . Pharmacogenomics of HIV therapy: summary of a workshop sponsored by the National Institute of Allergy and Infectious Diseases. HIV Clin Trials. 2011 Sep; 12(5): 277-85. PMID: 22180526, PMCID: PMC3322423, PII: H4HV83200516XH08, DOI: 10.1310/hct1205-277, ISSN: 1528-4336.
Qian HZ, Stinnette SE, Rebeiro PF, Kipp AM, Shepherd BE, Samenow CP, Jenkins CA, No P, McGowan CC, Hulgan T, Sterling TR. The relationship between injection and noninjection drug use and HIV disease progression. J Subst Abuse Treat [print-electronic]. 2011 Jul; 41(1): 14-20. PMID: 21349679, PMCID: PMC3110534, PII: S0740-5472(11)00014-6, DOI: 10.1016/j.jsat.2011.01.007, ISSN: 1873-6483.
Hulgan T, Haubrich R, Riddler SA, Tebas P, Ritchie MD, McComsey GA, Haas DW, Canter JA. European mitochondrial DNA haplogroups and metabolic changes during antiretroviral therapy in AIDS Clinical Trials Group Study A5142. AIDS. 2011 Jan 1/2/2011; 25(1): 37-47. PMID: 20871389, PMCID: PMC2995830, DOI: 10.1097/QAD.0b013e32833f9d02, ISSN: 1473-5571.
McGowan CC, Weinstein DD, Samenow CP, Stinnette SE, Barkanic G, Rebeiro PF, Sterling TR, Moore RD, Hulgan T. Drug use and receipt of highly active antiretroviral therapy among HIV-infected persons in two U.S. clinic cohorts. PLoS ONE. 2011; 6(4): e18462. PMID: 21541016, PMCID: PMC3081810, DOI: 10.1371/journal.pone.0018462, ISSN: 1932-6203.
Alves TP, Hulgan T, Wu P, Sterling TR, Stinnette SE, Rebeiro PF, Vincz AJ, Bruce M, Ikizler TA. Race, kidney disease progression, and mortality risk in HIV-infected persons. Clin J Am Soc Nephrol [print-electronic]. 2010 Dec; 5(12): 2269-75. PMID: 20876679, PMCID: PMC2994089, PII: CJN.00520110, DOI: 10.2215/CJN.00520110, ISSN: 1555-905X.
Shepherd BE, Jenkins CA, Rebeiro PF, Stinnette SE, Bebawy SS, McGowan CC, Hulgan T, Sterling TR. Estimating the optimal CD4 count for HIV-infected persons to start antiretroviral therapy. Epidemiology. 2010 Sep; 21(5): 698-705. PMID: 20585252, PMCID: PMC3086582, DOI: 10.1097/EDE.0b013e3181e97737, ISSN: 1531-5487.
Canter JA, Robbins GK, Selph D, Clifford DB, Kallianpur AR, Shafer R, Levy S, Murdock DG, Ritchie MD, Haas DW, Hulgan T, , . African mitochondrial DNA subhaplogroups and peripheral neuropathy during antiretroviral therapy. J. Infect. Dis. 2010 Jun 6/1/2010; 201(11): 1703-7. PMID: 20402593, PMCID: PMC2862090, DOI: 10.1086/652419, ISSN: 1537-6613.
Melekhin VV, Shepherd BE, Jenkins CA, Stinnette SE, Rebeiro PF, Bebawy SS, Rasbach DA, Hulgan T, Sterling TR. Postpartum discontinuation of antiretroviral therapy and risk of maternal AIDS-defining events, non-AIDS-defining events, and mortality among a cohort of HIV-1-infected women in the United States. AIDS Patient Care STDS. 2010 May; 24(5): 279-86. PMID: 20438375, PMCID: PMC2875979, DOI: 10.1089/apc.2009.0283, ISSN: 1557-7449.
Boger MS, Shintani A, Redhage LA, Mitchell V, Haas DW, Morrow JD, Hulgan T. Highly sensitive C-reactive protein, body mass index, and serum lipids in HIV-infected persons receiving antiretroviral therapy: a longitudinal study. J. Acquir. Immune Defic. Syndr. 2009 Dec 12/1/2009; 52(4): 480-7. PMID: 19911471, PMCID: PMC2794651, ISSN: 1944-7884.
Hulgan T, Donahue JP, Smeaton L, Pu M, Wang H, Lederman MM, Smith K, Valdez H, Pilcher C, Haas DW, . Oral cyclosporin A inhibits CD4 T cell P-glycoprotein activity in HIV-infected adults initiating treatment with nucleoside reverse transcriptase inhibitors. Eur. J. Clin. Pharmacol. 2009 Nov; 65(11): 1081-8. PMID: 19779705, PMCID: PMC2873632, DOI: 10.1007/s00228-009-0725-5, ISSN: 1432-1041.
Shepherd BE, Sterling TR, Moore RD, Raffanti SP, Hulgan T. Cross-cohort heterogeneity encountered while validating a model for HIV disease progression among antiretroviral initiators. J Clin Epidemiol [print-electronic]. 2009 Jul; 62(7): 729-37. PMID: 19108987, PMCID: PMC2747519, PII: S0895-4356(08)00257-6, DOI: 10.1016/j.jclinepi.2008.09.002, ISSN: 1878-5921.
Redhage LA, Shintani A, Haas DW, Emeagwali N, Markovic M, Oboho I, Mwenya C, Erdem H, Acosta EP, Morrow JD, Hulgan T. Clinical factors associated with plasma F2-isoprostane levels in HIV-infected adults. HIV Clin Trials. 2009 May; 10(3): 181-92. PMID: 19632957, PMCID: PMC2891063, PII: BG421Q1XL1393227, DOI: 10.1310/hct1003-181, ISSN: 1528-4336.
Kallianpur AR, Hulgan T. Pharmacogenetics of nucleoside reverse-transcriptase inhibitor-associated peripheral neuropathy. Pharmacogenomics. 2009 Apr; 10(4): 623-37. PMID: 19374518, PMCID: PMC2706211, DOI: 10.2217/pgs.09.14, ISSN: 1744-8042.
Lemly DC, Shepherd BE, Hulgan T, Rebeiro P, Stinnette S, Blackwell RB, Bebawy S, Kheshti A, Sterling TR, Raffanti SP. Race and sex differences in antiretroviral therapy use and mortality among HIV-infected persons in care. J. Infect. Dis. 2009 Apr 4/1/2009; 199(7): 991-8. PMID: 19220139, PII: 10.1086/597124, DOI: 10.1086/597124, ISSN: 0022-1899.
Asad S, Hulgan T, Raffanti SP, Daugherty J, Ray W, Sterling TR. Sociodemographic factors predict early discontinuation of HIV non-nucleoside reverse transcriptase inhibitors and protease inhibitors. J Natl Med Assoc. 2008 Dec; 100(12): 1417-24. PMID: 19110909, PMCID: PMC3816354, ISSN: 1943-4693.
Hulgan T. High-concentration capsaicin reduced pain in patients with HIV-associated polyneuropathy. Evid Based Med. 2008 Dec; 13(6): 183. PMID: 19043041, PII: 13/6/183, DOI: 10.1136/ebm.13.6.183, ISSN: 1473-6810.
El-Bejjani D, Hazen SL, Mackay W, Glass NE, Hulgan T, Tungsiripat M, McComsey GA. Higher plasma myeloperoxidase levels are not associated with an increased risk for cardiovascular events in HIV-infected adults. HIV Clin Trials. 2008 May; 9(3): 207-11. PMID: 18547908, PMCID: PMC2829429, PII: 0225W61M842505T2, DOI: 10.1310/hct0903-207, ISSN: 1528-4336.
Hulgan T, Klausner JD. Phosphodiesterase type-5 inhibitors and the reemerging HIV epidemic [letter]. JAMA. 2008 Mar 3/26/2008; 299(12): 1426. PMID: 18364484, PII: 299/12/1426-a, DOI: 10.1001/jama.299.12.1426, ISSN: 1538-3598.
Hulgan T, Tebas P, Canter JA, Mulligan K, Haas DW, Dubé M, Grinspoon S, Robbins GK, Motsinger AA, Kallianpur AR, . Hemochromatosis gene polymorphisms, mitochondrial haplogroups, and peripheral lipoatrophy during antiretroviral therapy. J. Infect. Dis. 2008 Mar 3/15/2008; 197(6): 858-66. PMID: 18419350, DOI: 10.1086/528697, ISSN: 0022-1899.
Canter JA, Haas DW, Kallianpur AR, Ritchie MD, Robbins GK, Shafer RW, Clifford DB, Murdock DG, Hulgan T. The mitochondrial pharmacogenomics of haplogroup T: MTND2*LHON4917G and antiretroviral therapy-associated peripheral neuropathy. Pharmacogenomics J [print-electronic]. 2008 Feb; 8(1): 71-7. PMID: 17684475, PII: 6500470, DOI: 10.1038/sj.tpj.6500470, ISSN: 1470-269X.
Motsinger AA, Haas DW, Hulgan T, Ritchie MD. Human genomic association studies: a primer for the infectious diseases specialist. J. Infect. Dis [print-electronic]. 2007 Jun 6/15/2007; 195(12): 1737-44. PMID: 17492588, PII: JID37481, DOI: 10.1086/518247, ISSN: 0022-1899.
Bress JN, Hulgan T, Lyon JA, Johnston CP, Lehmann H, Sterling TR. Agreement of decision analyses and subsequent clinical studies in infectious diseases. Am. J. Med. 2007 May; 120(5): 461.e1-9. PMID: 17466659, PMCID: PMC1909755, PII: S0002-9343(06)01149-1, DOI: 10.1016/j.amjmed.2006.08.032, ISSN: 1555-7162.
Oswald-Richter K, Grill SM, Leelawong M, Tseng M, Kalams SA, Hulgan T, Haas DW, Unutmaz D. Identification of a CCR5-expressing T cell subset that is resistant to R5-tropic HIV infection. PLoS Pathog. 2007 Apr; 3(4): e58. PMID: 17465678, PMCID: PMC1857714, PII: 06-PLPA-RA-0420R2, DOI: 10.1371/journal.ppat.0030058, ISSN: 1553-7374.
Hulgan T, Shepherd BE, Raffanti SP, Fusco JS, Beckerman R, Barkanic G, Sterling TR. Absolute count and percentage of CD4+ lymphocytes are independent predictors of disease progression in HIV-infected persons initiating highly active antiretroviral therapy. J. Infect. Dis [print-electronic]. 2007 Feb 2/1/2007; 195(3): 425-31. PMID: 17205482, PII: JID36919, DOI: 10.1086/510536, ISSN: 0022-1899.
Hulgan T, Haas DW. Toward a pharmacogenetic understanding of nucleotide and nucleoside analogue toxicity [editorial]. J. Infect. Dis [print-electronic]. 2006 Dec 12/1/2006; 194(11): 1471-4. PMID: 17083029, PII: JID36983, DOI: 10.1086/508550, ISSN: 0022-1899.
Hulgan T, Hughes M, Sun X, Smeaton LM, Terry E, Robbins GK, Shafer RW, Clifford DB, McComsey GA, Canter JA, Morrow JD, Haas DW. Oxidant stress and peripheral neuropathy during antiretroviral therapy: an AIDS clinical trials group study. J. Acquir. Immune Defic. Syndr. 2006 Aug 8/1/2006; 42(4): 450-4. PMID: 16791116, DOI: 10.1097/01.qai.0000226792.16216.1c, ISSN: 1525-4135.
Kallianpur AR, Hulgan T, Canter JA, Ritchie MD, Haines JL, Robbins GK, Shafer RW, Clifford DB, Haas DW. Hemochromatosis (HFE) gene mutations and peripheral neuropathy during antiretroviral therapy. AIDS. 2006 Jul 7/13/2006; 20(11): 1503-13. PMID: 16847405, PII: 00002030-200607130-00005, DOI: 10.1097/01.aids.0000237366.56864.3c, ISSN: 0269-9370.
Hulgan T, Raffanti S, Kheshti A, Blackwell RB, Rebeiro PF, Barkanic G, Ritz B, Sterling TR. CD4 lymphocyte percentage predicts disease progression in HIV-infected patients initiating highly active antiretroviral therapy with CD4 lymphocyte counts >350 lymphocytes/mm3. J. Infect. Dis [print-electronic]. 2005 Sep 9/15/2005; 192(6): 950-7. PMID: 16107946, PII: JID33585, DOI: 10.1086/432955, ISSN: 0022-1899.
Hulgan T, Haas DW, Haines JL, Ritchie MD, Robbins GK, Shafer RW, Clifford DB, Kallianpur AR, Summar M, Canter JA. Mitochondrial haplogroups and peripheral neuropathy during antiretroviral therapy: an adult AIDS clinical trials group study. AIDS. 2005 Sep 9/2/2005; 19(13): 1341-9. PMID: 16103764, PII: 00002030-200509020-00001, ISSN: 0269-9370.
Hulgan T, Sterling TR, Daugherty J, Arbogast PG, Raffanti S, Ray W. Prescribing of contraindicated protease inhibitor and statin combinations among HIV-infected persons. J. Acquir. Immune Defic. Syndr. 2005 Mar 3/1/2005; 38(3): 277-82. PMID: 15735444, PII: 00126334-200503010-00005, ISSN: 1525-4135.
Haas DW, Ribaudo HJ, Kim RB, Tierney C, Wilkinson GR, Gulick RM, Clifford DB, Hulgan T, Marzolini C, Acosta EP. Pharmacogenetics of efavirenz and central nervous system side effects: an Adult AIDS Clinical Trials Group study. AIDS. 2004 Dec 12/3/2004; 18(18): 2391-400. PMID: 15622315, PII: 00002030-200412030-00006, ISSN: 0269-9370.
Hulgan T, Rosenbloom ST, Hargrove F, Talbert DA, Arbogast PG, Bansal P, Miller RA, Kernodle DS. Oral quinolones in hospitalized patients: an evaluation of a computerized decision support intervention. J. Intern. Med. 2004 Oct; 256(4): 349-57. PMID: 15367178, PII: JIM1375, DOI: 10.1111/j.1365-2796.2004.01375.x, ISSN: 0954-6820.
Chan SY, Hulgan T, D'Aquila RT. The Role of Baseline HIV-1 Resistance Testing in Patients with Established Infection. Curr Infect Dis Rep. 2004 Jun; 6(3): 243-9. PMID: 15142489, ISSN: 1523-3847.
Hulgan T, Morrow J, D'Aquila RT, Raffanti S, Morgan M, Rebeiro P, Haas DW. Oxidant stress is increased during treatment of human immunodeficiency virus infection. Clin. Infect. Dis [print-electronic]. 2003 Dec 12/15/2003; 37(12): 1711-7. PMID: 14689356, PII: CID31711, DOI: 10.1086/379776, ISSN: 1537-6591.
Haas DW, Johnson BW, Spearman P, Raffanti S, Nicotera J, Schmidt D, Hulgan T, Shepard R, Fiscus SA. Two phases of HIV RNA decay in CSF during initial days of multidrug therapy. Neurology. 2003 Nov 11/25/2003; 61(10): 1391-6. PMID: 14638961, ISSN: 1526-632X.
Hulgan T, Donahue JP, Hawkins C, Unutmaz D, D'Aquila RT, Raffanti S, Nicotera F, Rebeiro P, Erdem H, Rueff M, Haas DW. Implications of T-cell P-glycoprotein activity during HIV-1 infection and its therapy. J. Acquir. Immune Defic. Syndr. 2003 Oct 10/1/2003; 34(2): 119-26. PMID: 14526200, ISSN: 1525-4135.
Donahue JP, Dowdy D, Ratnam KK, Hulgan T, Price J, Unutmaz D, Nicotera J, Raffanti S, Becker M, Haas DW. Effects of nelfinavir and its M8 metabolite on lymphocyte P-glycoprotein activity during antiretroviral therapy. Clin. Pharmacol. Ther. 2003 Jan; 73(1): 78-86. PMID: 12545146, PII: S0009923602176120, DOI: 10.1067/mcp.2003.11, ISSN: 0009-9236.
Sherertz RJ, Ely EW, Westbrook DM, Gledhill KS, Streed SA, Kiger B, Flynn L, Hayes S, Strong S, Cruz J, Bowton DL, Hulgan T, Haponik EF. Education of physicians-in-training can decrease the risk for vascular catheter infection. Ann. Intern. Med. 2000 Apr 4/18/2000; 132(8): 641-8. PMID: 10766683, PII: 200004180-00007, ISSN: 0003-4819.
Moore RB, Hulgan TM, Green JW, Jenkins LD. Increased susceptibility of the sickle cell membrane Ca2+ + Mg(2+)-ATPase to t-butylhydroperoxide: protective effects of ascorbate and desferal. Blood. 1992 Mar 3/1/1992; 79(5): 1334-41. PMID: 1531618, ISSN: 0006-4971.